Cited by 961Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchExtracellular vesicles in disease

Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case‐control study

Open access
Fiandaca, Massimo S., Kapogiannis, Dimitrios, Mapstone, Mark, Boxer, Adam, Eitan, Erez, Schwartz, Janice B., Abner, Erin L., Petersen, Ronald C. +3 more·2015·Alzheimer's & Dementia

Abstract

Background: Proteins pathogenic in Alzheimer's disease (AD) were extracted from neurally derived blood exosomes and quantified to develop biomarkers for the staging of sporadic AD. Methods: Blood exosomes obtained at one time‐point from patients with AD (n = 57) or frontotemporal dementia (FTD) (n = 16), and at two time‐points from others (n = 24) when cognitively normal and 1 to 10 years later when diagnosed with AD were enriched for neural sources by immunoabsorption. AD‐pathogenic exosomal proteins were extracted and quantified by enzyme‐linked immunosorbent assays. Results: Mean exosomal levels of total tau, P‐T181‐tau, P‐S396‐tau, and amyloid β 1–42 (Aβ1–42) for AD and levels of P‐T181‐tau and Aβ1–42 for FTD were significantly higher than for case‐controls. Step‐wise discriminant modeling incorporated P‐T181‐tau, P‐S396‐tau, and Aβ1–42 in AD, but only P‐T181‐tau in FTD. Classification of 96.4% of AD patients and 87.5% of FTD patients was correct. In 24 AD patients, exosomal levels of P‐S396‐tau, P‐T181‐tau, and Aβ1–42 were significantly higher than for controls both 1 to 10 years before and when diagnosed with AD. Conclusions: Levels of P‐S396‐tau, P‐T181‐tau, and Aβ1–42 in extracts of neurally derived blood exosomes predict the development of AD up to 10 years before clinical onset.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2014.06.008

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Fiandaca, M. S., Kapogiannis, D., Mapstone, M., Boxer, A., Eitan, E., Schwartz, J. B., Abner, E. L., Petersen, R. C., Federoff, H. J., Miller, B. L., & Goetzl, E. J.
Affiliations
  • Georgetown University Medical Center (US)
  • National Institute on Aging (US)
  • University of Rochester Medicine (US)
  • University of California San Francisco Medical Center (US)
  • University of Kentucky (US)
  • Mayo Clinic (US)
Corresponding author
Goetzl, Edward J.
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2014-08-14
Volume
11
Issue
6
Pages
600
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W1995903088
Cited by
959
References
31
Citations by year
2026: 77 · 2025: 91 · 2024: 109 · 2023: 86 · 2022: 115 · 2021: 106 · 2020: 105 · 2019: 93 · 2018: 46 · 2017: 50 · 2016: 50 · 2015: 24 · 2014: 3 · 2013: 1
FWCI
28.15
Type
journal article
Language
en
Open access
Locations
  • Alzheimer s & Dementia (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Institute on Aging (NIA RO1AG030753)
  • National Institutes of Health (UK ADC P30 AG028383)
  • Genentech
  • Alzheimer's Association
  • Association for Frontotemporal Degeneration
  • Alzheimer's Drug Discovery Foundation
  • Pfizer
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
Keywords
preclinical Alzheimer's disease, blood exosomes
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Cross-Sectional Studies, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Peptide Fragments, Phosphorylation, Retrospective Studies, Severity of Illness Index, Time Factors, Biomarkers, Discriminant Analysis, Case-Control Studies, Amyloid beta-Peptides, tau Proteins, Exosomes, Frontotemporal Dementia, Prodromal Symptoms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review